Как празолы или Н2-блокеры и у кого предотвращают ЖКК на фоне приема дабигатрана:
Among the 5041 patients newly prescribed dabigatran, 124 (2.5%) developed GIB during follow-up (4.2/100 patient-years). The risk of GIB in this population increased among patients 75 y old or older (IRR, 2.47; 95% confidence interval [CI], 1.66-3.68), patients with a history of peptic ulcers or GIB (IRR, 2.31; 95% CI, 1.54-3.46), and patients who used aspirin (IRR, 1.52; 95% CI, 1.03-2.24). Concomitant use of GPAs was associated with a reduced risk of GIB (IRR, 0.52; 95% CI, 0.35-0.77). Subcategory analysis showed that use of proton-pump inhibitors (IRR, 0.53; 95% CI, 0.31-0.91) or histamine type-2 receptor antagonists (IRR, 0.61; 95% CI, 0.40-0.94) were associated with lower risk of GIB. Further analysis revealed that the risk reduction by GPAs was significant for only upper GIB (IRR, 0.29; 95% CI, 0.15-0.54) and only for patients with prior history of peptic ulcers or GIB (IRR, 0.14; 95% CI, 0.06-0.30).
---
Gastroenterology. 2015 May 7.
Prevention of Dabigatran-related Gastrointestinal Bleeding With Gastroprotective Agents: A Population-Based Study.
Chan EW, и соавт.
[Ссылки доступны только зарегистрированным пользователям ]
|